SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Davide Serrano, Matteo Lazzeroni, Bernardo Bonanni, Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches, Molecular Oncology, 2015, 9, 5, 1008

    CrossRef

  2. 2
    Katrina B. Mitchell, Henry Kuerer, Ductal Carcinoma In Situ: Treatment Update and Current Trends, Current Oncology Reports, 2015, 17, 11

    CrossRef

  3. 3
    Henry M Kuerer, Ductal carcinomain situ: treatment or active surveillance?, Expert Review of Anticancer Therapy, 2015, 15, 7, 777

    CrossRef

  4. You have free access to this content4
    Karen Colbert Maresso, Kenneth Y. Tsai, Powel H. Brown, Eva Szabo, Scott Lippman, Ernest T. Hawk, Molecular cancer prevention: Current status and future directions, CA: A Cancer Journal for Clinicians, 2015, 65, 5
  5. 5
    K. E. Williams, N. L. P. Barnes, A. Cramer, R. Johnson, K. Cheema, J. Morris, M. Howe, N. J. Bundred, Molecular phenotypes of DCIS predict overall and invasive recurrence, Annals of Oncology, 2015, 26, 5, 1019

    CrossRef

  6. 6
    G. Curigliano, D. Disalvatore, A. Esposito, G. Pruneri, M. Lazzeroni, A. Guerrieri-Gonzaga, A. Luini, R. Orecchia, A. Goldhirsch, N. Rotmensz, B. Bonanni, G. Viale, Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ, Annals of Oncology, 2015, 26, 4, 682

    CrossRef

  7. 7
    Samantha C. Sodergren, Ellen Copson, Alice White, Fabio Efficace, Mirjam Sprangers, Deborah Fitzsimmons, Andrew Bottomley, Colin D. Johnson, Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group, Targeted Oncology, 2015,

    CrossRef

  8. 8
    Signe Borgquist, Wenjing Zhou, Karin Jirström, Rose-Marie Amini, Thomas Sollie, Therese Sørlie, Carl Blomqvist, Salma Butt, Fredrik Wärnberg, The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study, BMC Cancer, 2015, 15, 1

    CrossRef

  9. 9
    Beate C. Litzenburger, Powel H. Brown, Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer, Current Breast Cancer Reports, 2014, 6, 2, 96

    CrossRef

  10. 10
    Dirce M. Carraro, Eliana V. Elias, Victor P. Andrade, Ductal carcinomain situof the breast: morphological and molecular features implicated in progression, Bioscience Reports, 2014, 34, 1, 19

    CrossRef

  11. 11
    Jin Hee Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Sung Whan Ha, Kyubo Kim, Yong Bae Kim, Ji Woon Yea, Min Kyu Kang, Kyung Hwan Shin, Dong Won Kim, Ji Hae Lee, Chang-Ok Suh, Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer: a multicenter, retrospective study in Korea (KROG 11-04), Breast Cancer Research and Treatment, 2014, 146, 2, 341

    CrossRef

  12. 12
    Gillian Farnie, Rachael Johnson, Kathryn Williams Williams, Robert Clarke, Nigel Bundred, Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS), Cell Cycle, 2014, 13, 3, 418

    CrossRef

  13. 13
    Laura G Estévez, Ana Suarez-Gauthier, Elena García, Cristina Miró, Isabel Calvo, María Fernández-Abad, Mercedes Herrero, Manuel Marcos, Cristina Márquez, Fernando Lopez Ríos, Sofía Perea, Manuel Hidalgo, Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ, Breast Cancer Research, 2014, 16, 4, R76

    CrossRef

  14. 14
    Kalliopi P. Siziopikou, Ductal Carcinoma In Situ of the Breast: Current Concepts and Future Directions, Archives of Pathology & Laboratory Medicine, 2013, 137, 4, 462

    CrossRef

  15. 15
    Chloe Constantinou, Ian S. Fentiman, Ductal Carcinoma in Situ Treatment Requires a Multidisciplinary Approach, Journal of Cancer Therapy, 2013, 04, 07, 1203

    CrossRef

  16. 16
    Jae Myoung Noh, Jihae Lee, Doo Ho Choi, Eun Yoon Cho, Seung Jae Huh, Won Park, Seok Jin Nam, Jeong Eon Lee, Won-Ho Kil, HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy, The Breast, 2013, 22, 5, 894

    CrossRef

  17. 17
    David P. Boyle, Paul Mullan, Manuel Salto-Tellez, Molecular mapping the presence of druggable targets in preinvasive and precursor breast lesions: A comprehensive review of biomarkers related to therapeutic interventions, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2013, 1835, 2, 230

    CrossRef

  18. 18
    Aimee Mackey, Rachel Greenup, E. Shelley Hwang, New Treatment Paradigms for Patients with Ductal Carcinoma In Situ, Current Breast Cancer Reports, 2013, 5, 2, 86

    CrossRef

  19. 19
    Kalliopi P. Siziopikou, Stewart J. Anderson, Melody A. Cobleigh, Thomas B. Julian, Douglas W. Arthur, Ping Zheng, Eleftherios P. Mamounas, Eduardo R. Pajon, Robert J. Behrens, Janice F. Eakle, Nick C. Leasure, James N. Atkins, Jonathan A. Polikoff, Thomas E. Seay, Worta J. McCaskill-Stevens, Rachel Rabinovitch, Joseph P. Costantino, Norman Wolmark, Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43, Breast Cancer Research and Treatment, 2013, 142, 2, 415

    CrossRef

  20. 20
    S. Masson, A. Bahl, The Management of Ductal Carcinoma in Situ: Current Controversies and Future Directions, Clinical Oncology, 2013, 25, 5, 275

    CrossRef

  21. 21
    Nuran Serce, Annette Gnatzy, Susanne Steiner, Henning Lorenzen, Jutta Kirfel, Reinhard Buettner, Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast, BMC Clinical Pathology, 2012, 12, 1, 13

    CrossRef

  22. 22
    Gunter von Minckwitz, Silvia Darb-Esfahani, Sibylle Loibl, Jens Huober, Hans Tesch, Christine Solbach, Frank Holms, Holger Eidtmann, Klaus Dietrich, Marianne Just, Michael R. Clemens, Claus Hanusch, Iris Schrader, Stephan Henschen, Gerald Hoffmann, Katharina Tiemann, Kurt Diebold, Michael Untch, Carsten Denkert, Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40), Breast Cancer Research and Treatment, 2012, 132, 3, 863

    CrossRef

  23. 23
    T.B. Julian, M.A. Cobleigh, K.P. Siziopikou, Biologic and Immunologic Effects of Preoperative Trastuzumab for Ductal Carcinoma In Situ of the Breast, Breast Diseases: A Year Book Quarterly, 2011, 22, 3, 282

    CrossRef